Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Otto, M. W. Articles by Pollack, M. H. Search for Related Content PubMed Citation Articles by Otto, M. W. Articles by Pollack, M. H. Panic Disorder Antidepressants

An Effect-Size Analysis of the Relative Efficacy and Tolerability of Serotonin Selective Reuptake Inhibitors for Panic Disorder

OBJECTIVE: Serotonin selective reuptake inhibitors (SSRIs) are now considered the first-line pharmacotherapy for panic disorder. The preferential use and the presumption of greater tolerability of SSRIs relative to older agents, such as tricyclic antidepressants, occurred without direct comparisons between the two classes of medication. In this study the authors used an effect-size analysis to provide an initial comparison. METHOD: The authors conducted an effect-size analysis of 12 placebo-controlled, efficacy trials of SSRIs for panic disorder and compared these results to findings obtained in a recent meta-analysis of non-SSRI treatments for panic disorder. RESULTS: The mean effect size for acute treatment outcome for SSRIs relative to placebo was 0.55, not significantly different from that for antidepressants in general (0.55) and for imipramine in particular (0.48). More recent studies of SSRIs, and studies using larger samples, were associated with lower effect sizes. No significant differences were found in dropout rates between those taking SSRIs and those taking older agents during acute treatment. CONCLUSIONS: An effect-size analysis of controlled studies of treatments for panic disorder revealed no significant differences between SSRIs and older antidepressants in terms of efficacy or tolerability in short-term trials. An inverse relationship was evident between sample size and effect size for SSRIs. Early studies of small samples may have led to initial overestimations of the efficacy of SSRIs for panic disorder.

This article has been cited by other articles:

				B. A. Marcks, R. B. Weisberg, and M. B. Keller Psychiatric Treatment Received by Primary Care Patients With Panic Disorder With and Without Agoraphobia Psychiatr Serv, June 1, 2009; 60(6): 823 - 830. [Abstract] [Full Text] [PDF]

				L. Dutra, G. Stathopoulou, S. L. Basden, T. M. Leyro, M. B. Powers, and M. W. Otto A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders Am J Psychiatry, February 1, 2008; 165(2): 179 - 187. [Abstract] [Full Text] [PDF]

				R. B. Hidalgo, L. A. Tupler, and J. R. T. Davidson An effect-size analysis of pharmacologic treatments for generalized anxiety disorder J Psychopharmacol, November 1, 2007; 21(8): 864 - 872. [Abstract] [PDF]

				B. H. Levine and R. C. Albucher Patient Management Exercise FOR PSYCHOPHARMACOLOGY Focus, September 1, 2006; 4(4): 496. [Abstract] [Full Text] [PDF]

				W. J. Katon Clinical practice. Panic disorder. N. Engl. J. Med., June 1, 2006; 354(22): 2360 - 2367. [Full Text] [PDF]

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				J. BRADWEJN, A. AHOKAS, D. J. STEIN, E. SALINAS, G. EMILIEN, and T. WHITAKER Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study The British Journal of Psychiatry, October 1, 2005; 187(4): 352 - 359. [Abstract] [Full Text] [PDF]

				B. Lowe, K. Grafe, C. Ufer, K. Kroenke, E. Grunig, W. Herzog, and M. M. Borst Anxiety and Depression in Patients With Pulmonary Hypertension Psychosom Med, November 1, 2004; 66(6): 831 - 836. [Abstract] [Full Text] [PDF]

				S. E. Bruce, R. G. Vasile, R. M. Goisman, C. Salzman, M. Spencer, J. T. Machan, and M. B. Keller Are Benzodiazepines Still the Medication of Choice for Patients With Panic Disorder With or Without Agoraphobia? Am J Psychiatry, August 1, 2003; 160(8): 1432 - 1438. [Abstract] [Full Text] [PDF]

				S. Kumar and M. O. Browne What are the effects of drug treatments for panic disorder? Evid. Based Ment. Health, May 1, 2003; 6(2): 34 - 37. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us